Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* STEMI ≤ 12 hours (or STEMI equivalent).~* No contra - indications for primary PCI.~* No contra - indications for abciximab.~* Informed consent from the patient.~Exclusion Criteria:~* Contra - indication for primary PCI: History of peripheral/coronary artery disease that is inaccessible for angiography or PCI.~* Contra - indications for GPI: Ongoing bleeding, bleeding diathesis, cerebrovascular accident \< 6 months, major surgery/trauma \< 6 months, platelet count \< 100.000 mm3 , intracranial arteriovenous malformation or neoplasm, malignant hypertension, INR \>1.5, severe hepatic dysfunction~* Contra - indications for clopidogrel:~  * Severe liver dysfunction, pathological bleeding disorders such as peptic ulcer or intracranial bleeding.~ * Thrombolytic therapy \< 24 hours.~ * Therapy with GPI \< 24 hours.~ * Anticoagulation therapy.~* Co - morbid conditions with a predictable fatal outcome in the short run.~* No informed consent: refusal, coma, artificial respiration, impaired mentation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bare metal stent (BMS) (Type: ACTIVE_COMPARATOR): None
- Drug eluting stent (DES) (Type: ACTIVE_COMPARATOR): None
- Abciximab (Type: ACTIVE_COMPARATOR): None
- No abciximab (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).